TIGIT-PVR免疫检查点轴在女性生殖系统恶性肿瘤中的研究进展
摘要
蛋白（Ig）和免疫受体酪氨酸抑制基序超家族（ITIM）结构域的T细胞免疫受体，在人体中广泛表达。TIGIT与脊
髓灰质炎病毒受体PVR（又称CD155，也被称为NECL-5）结合，发挥免疫抑制作用，与PD1/PD-L1在免疫环境中
的作用类似。近年来，TIGIT-PVR免疫检查点轴在恶性肿瘤发生发展中的作用逐渐成为研究热点，其在各种恶性肿
瘤中的表达存在差异性，促进或抑制肿瘤生长和进展，且与预后密切相关，是恶性肿瘤潜在的治疗靶点。本文旨在
对TIGIT-PVR免疫检查点轴在各种恶性肿瘤中的表达特征及免疫调控进行综述，探讨其作为新型生物标志物或治疗
靶点的可能性，为肿瘤免疫治疗提供新思路。
关键词
全文:
PDF参考
[1]CHAN C J, ANDREWS D M, SMYTH M J.
Receptors that interact with nectin and nectin-like proteins
in the immunosurveillance and immunotherapy of cancer [J].
Current opinion in immunology, 2012, 24(2): 246-51.
[2]YU X, HARDEN K, GONZALEZ L C, et al.
The surface protein TIGIT suppresses T cell activation by
promoting the generation of mature immunoregulatory
dendritic cells [J]. Nature immunology, 2009, 10(1): 48-57.
[3]BOLES K S, VERMI W, FACCHETTI F, et al. A
novel molecular interaction for the adhesion of follicular CD4
T cells to follicular DC [J]. European journal of immunology,
2009, 39(3): 695-703.
[4]LEVIN S D, TAFT D W, BRANDT C S, et al.
Vstm3 is a member of the CD28 family and an important
modulator of T-cell function [J]. European journal of
immunology, 2011, 41(4): 902-15.
[5]TAKAI Y, MIYOSHI J, IKEDA W, et al. Nectins
and nectin-like molecules: roles in contact inhibition of cell
movement and proliferation [J]. Nature reviews Molecular cell
biology, 2008, 9(8): 603-15.
[6]KOIKE S, HORIE H, ISE I, et al. The poliovirus
receptor protein is produced both as membrane-bound and
secreted forms [J]. The EMBO journal, 1990, 9(10): 3217-24.
[7]STANIETSKY N, SIMIC H, ARAPOVIC J, et al.
The interaction of TIGIT with PVR and PVRL2 inhibits
human NK cell cytotoxicity [J]. Proceedings of the National
Academy of Sciences of the United States of America, 2009,
106(42): 17858-63.
[ 8 ] J O H N S T O N R J , C O M P S - A G R A R L ,
HACKNEY J, et al. The immunoreceptor TIGIT regulates
antitumor and antiviral CD8(+) T cell effector function [J].
Cancer cell, 2014, 26(6): 923-37.
[9]SMAZYNSKI J, HAMILTON P T, THORNTON
S, et al. The immune suppressive factors CD155 and PD-L1
show contrasting expression patterns and immune correlates
in ovarian and other cancers [J]. Gynecologic oncology, 2020,
158(1): 167-77.
[10]MAAS R J, HOOGSTAD-VAN EVERT J S,
VAN DER MEER J M, et al. TIGIT blockade enhances
functionality of peritoneal NK cells with altered expression of
DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian
cancer [J]. Oncoimmunology, 2020, 9(1): 1843247.
[11]LIU L, WANG A, LIU X, et al. Blocking TIGIT/
CD155 signalling reverses CD8(+) T cell exhaustion and
enhances the antitumor activity in cervical cancer [J]. Journal
of translational medicine, 2022, 20(1): 280.
[12]XIE B F, XIA Y, LIN D H, et al. Pan-Cancer Gene
Analysis of m6A Modification and Immune Infiltration in
Uterine Corpus Endometrial Carcinoma [J]. Computational
intelligence and neuroscience, 2022, 2022: 6530884.
[13]JIANG F, MAO M, JIANG S, et al. PD-1 and
TIGIT coexpressing CD8 + CD103 + tissue-resident
memory cells in endometrial cancer as potential targets for
immunotherapy [J]. International immunopharmacology,
2024, 127: 111381.
[14]TANG L, SHA M, GUO T, et al. Expression and
Clinical Significance of TIGIT in Primary Breast Cancer [J].
International journal of general medicine, 2023, 16: 2405-17.
[15]GUO C, LUO Z, ISMTULA D, et al. TIGIT
as a Novel Prognostic Marker for Immune Infiltration in
Invasive Breast Cancer [J]. Combinatorial chemistry & high
throughput screening, 2023, 26(3): 639-51.
[16]HUANG M, YU X, WANG Q, et al. The
immune checkpoint TIGIT/CD155 promotes the exhaustion
of CD8 + T cells in TNBC through glucose metabolic
reprogramming mediated by PI3K/AKT/mTOR signaling [J].
Cell communication and signaling : CCS, 2024, 22(1): 35.
[17]BOISSIèRE-MICHOT F, CHATEAU M C,
THéZENAS S, et al. Correlation of the TIGIT-PVR
immune checkpoint axis with clinicopathological features in
triple-negative breast cancer [J]. Frontiers in immunology,
2022, 13: 1058424.
[18]CHU X, TIAN W, WANG Z, et al. Co-inhibition
of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy:
Mechanisms and Clinical Trials [J]. Molecular cancer, 2023,
22(1): 93.
[19]MU S, LIANG Z, WANG Y, et al. PD-L1/TIGIT
bispecific antibody showed survival advantage in animal model
[J]. Clinical and translational medicine, 2022, 12(5): e754.
[20]RACHEL S, STEPHEN A, VINCENT R, et al.
474 Phase 1 study of SEA-TGT, a human, nonfucosylated
anti-TIGIT monoclonal antibody with enhanced [J]. Journal
for immunotherapy of cancer, 2021, 9.
Refbacks
- 当前没有refback。
